An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Blood

Volumn 110, Issue 13, 2007, Pages 4427-4435

  Guzman, Monica L ^a   Rossi, Randall M ^a   Neelakantan, Sundar ^b   Li, Xiaojie ^a   Corbett, Cheryl A ^a   Hassane, Duane C ^a   Becker, Michael W ^a   Bennett, John M ^a   Sullivan, Edmund ^c   Lachowicz, Joshua L ^d   Vaughan, Andrew ^e   Sweeney, Christopher J ^f   Matthews, William ^g   Carroll, Martin ^h   Liesveld, Jane L ^a   Crooks, Peter A ^b   Jordan, Craig T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Advanced Veterinary Services   (United States)

^d Redbank Veterinary Hospital   (United States)

^e Las Vegas Veterinary Referral Center   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Leuchemix Inc   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; DERACOXIB; DIMETHYLAMINOPARTHENOLIDE; DIURETIC AGENT; FAMOTIDINE; HYDROCODONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESNA; PARTHENOLIDE; PREDNISONE; PROKINETIC AGENT; PROTEIN P53; SEDATIVE AGENT; UNCLASSIFIED DRUG; SESQUITERPENE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHATIC LEUKEMIA; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL; TUMOR XENOGRAFT; ANIMAL; BIOAVAILABILITY; CANCER STEM CELL; CELL CULTURE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DRUG DESIGN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASTIC STEM CELLS; NF-KAPPA B; OXIDATIVE STRESS; SESQUITERPENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39649125467     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-090621     Document Type: Article

References (24)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
3. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood. 2004;104:2919-2925.
4. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056-2064.
5. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
6. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101:3142-3149.
7. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105:4163-4169.
8. Killmann SA. Acute leukaemia: development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the "sleeper-to-feeder" stem cell hypothesis. Baillieres Clin Haematol. 1991;4:577-598.
9. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520-6527.
10. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004;23:7178-7187.
11. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
12. Guzman ML, Upchurch D, Grimes B, et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001;97:2177-2179.
13. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
14. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 2000;1470:M55-M62.
15. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297-309.
16. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99:16220-16225.
17. Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control. 2004;11:97-104.
18. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005;4:1004-1012.
19. + cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow. J Exp Med. 1992;175:1501-1509.
20. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003;23:8992-9002.
21. Jeong WS, Jun M, Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal. 2006;8:99-106.
22. Tanaka T, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle. 2006;5:1940-1945.
23. Jordan CT, Guzman ML, Noble M. Mechanisms of disease: cancer stem cells. New Engl J Med. 2006;355:55-66.
24. Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol. 2007;14:813-823.